EP Patent

EP4240735A1 — Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Assigned to Nimmune Biopharma Inc · Expires 2023-09-13 · 3y expired

What this patent protects

Crystalline forms of piperazine-1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2- yl)methanone), compositions containing one or more crystalline forms of piperazine- 1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2-yl)methanone), processes for preparing crystalline fo…

USPTO Abstract

Crystalline forms of piperazine-1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2- yl)methanone), compositions containing one or more crystalline forms of piperazine- 1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2-yl)methanone), processes for preparing crystalline forms of piperazine-1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2- yl)methanone), and methods of using crystalline forms of piperazine- 1,4-diylbis((6-(1 H -benzo[ d ]imidazo-2-yl)pyridine-2-yl)methanone).

Drugs covered by this patent

Patent Metadata

Patent number
EP4240735A1
Jurisdiction
EP
Classification
—
Expires
2023-09-13
Drug substance claim
No
Drug product claim
No
Assignee
Nimmune Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.